Home › Compare › ACUR vs JNJ

ACUR vs JNJ: Dividend Comparison 2026

ACUR yields 20000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACUR wins by $52481917574412746752.00M in total portfolio value
10 years
ACUR
ACUR
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ACUR calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ACUR vs JNJ

📍 ACUR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACURJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACUR + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ACUR pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACUR
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ACUR beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACUR + JNJ for your $10,000?

ACUR: 50%JNJ: 50%
100% JNJ50/50100% ACUR
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ACUR
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-635.4
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACUR buys
0
JNJ buys
0
No recent congressional trades found for ACUR or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACURJNJ
Forward yield20000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$52481917574412746752.00M ✓$20.0K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$827.78
Total dividends collected$52448189483771600896.00M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ACUR vs JNJ ($10,000, DRIP)

YearACUR PortfolioACUR Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,010,700$2,000,000.00$10,676$355.77+$2.00M → ACUR
2$377,983,225$375,831,775.70$11,407$389.39+$377.97M → ACUR
3$66,433,479,469$66,029,037,418.28$12,198$426.53+$66433.47M → ACUR
4$10,916,985,471,987$10,845,901,648,955.73$13,056$467.62+$10916985.46M → ACUR
5$1,677,384,363,769,318$1,665,703,189,314,291.80$13,987$513.12+$1677384363.76M → ACUR
6$240,985,175,079,139,100$239,190,373,809,905,920.00$14,998$563.56+$240985175079.12M → ACUR
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$16,098$619.52+$32373573631143.68M → ACUR
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$17,295$681.69+$4066766648320630.00M → ACUR
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$18,599$750.82+$477730483406513344.00M → ACUR
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$20,022$827.78+$52481917574412746752.00M → ACUR

ACUR vs JNJ: Complete Analysis 2026

ACUR — Stock

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Full ACUR Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ACUR vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACUR vs SCHDACUR vs JEPIACUR vs OACUR vs KOACUR vs MAINACUR vs ABBVACUR vs MRKACUR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.